Are you a Health Professional? Jump over to the doctors only platform. Click Here

Neurogen Arthritis Drug a Failure

Print Friendly, PDF & Email

Neurogen Corp. said on Tuesday it is unlikely it will continue development of its drug NGD 2000-1 for adult rheumatoid arthritis patients after it failed to meet a clinical trial’s objective.

Neurogen Corp. said on Tuesday it is unlikely it will continue development of its drug NGD 2000-1 for adult rheumatoid arthritis patients after it failed to meet a clinical trial’s objective. The drug did not show an effect regarding a change in C-reactive proteins, a marker of rheumatoid arthritis in patient blood samples, when compared with a placebo, the company said. (Source: Reuters Health, June 2004)


Print Friendly, PDF & Email

Dates

Posted On: 16 June, 2004
Modified On: 7 December, 2013

Tags



Created by: myVMC